ViroPharma, Inc. (NASDAQ:VPHM)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.

Recs

5
Player Avatar adavisclan (88.14) Submitted: 2/27/2009 10:42:13 AM : Outperform Start Price: $5.95 VPHM Score: +601.99

2008 4th qtr missed estimates which was disappointing, however forward looking still is favorable. In the 4th qtr, they took a one time write down of $2.3 million for closing their corporate headquarters. While many firms unwisely cut R&D expenses when in troubled times, ViroPharma actually increased 4th qtr R&D expenses by 76% which should help fill pipelines to replace Vancocin if and when it goes generic at some point. 2009 guidance did not put revenues in for Cinryze due to uncertainty. This is an upside with high probablity. They continue to generate strong free cash flows.

Featured Broker Partners


Advertisement